| MRI-targeted or standard biopsy for prostate-cancer diagnosis V Kasivisvanathan, AS Rannikko, M Borghi, V Panebianco, LA Mynderse, ... New England Journal of Medicine 378 (19), 1767-1777, 2018 | 3054 | 2018 |
| Apalutamide treatment and metastasis-free survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... New England Journal of Medicine 378 (15), 1408-1418, 2018 | 1432 | 2018 |
| The diagnostic value of PET/CT imaging with the 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer A Afshar-Oromieh, E Avtzi, FL Giesel, T Holland-Letz, HG Linhart, M Eder, ... European journal of nuclear medicine and molecular imaging 42, 197-209, 2015 | 1140 | 2015 |
| Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer A Afshar-Oromieh, CM Zechmann, A Malcher, M Eder, M Eisenhut, ... European journal of nuclear medicine and molecular imaging 41, 11-20, 2014 | 1084 | 2014 |
| PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions A Afshar-Oromieh, A Malcher, M Eder, M Eisenhut, HG Linhart, ... European journal of nuclear medicine and molecular imaging 40, 486-495, 2013 | 1065 | 2013 |
| F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients FL Giesel, B Hadaschik, J Cardinale, J Radtke, M Vinsensia, W Lehnert, ... European journal of nuclear medicine and molecular imaging 44, 678-688, 2017 | 603 | 2017 |
| Detection of clinically significant prostate cancer using magnetic resonance imaging–ultrasound fusion targeted biopsy: a systematic review M Valerio, I Donaldson, M Emberton, B Ehdaie, BA Hadaschik, LS Marks, ... European urology 68 (1), 8-19, 2015 | 550 | 2015 |
| Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT M Eiber, K Herrmann, J Calais, B Hadaschik, FL Giesel, M Hartenbach, ... Journal of Nuclear Medicine 59 (3), 469-478, 2018 | 540 | 2018 |
| Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: recommendations from an International Working Group CM Moore, V Kasivisvanathan, S Eggener, M Emberton, JJ Fütterer, ... European urology 64 (4), 544-552, 2013 | 478 | 2013 |
| Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy CM Zechmann, A Afshar-Oromieh, T Armor, JB Stubbs, W Mier, ... European journal of nuclear medicine and molecular imaging 41, 1280-1292, 2014 | 427 | 2014 |
| Comparison of PET/CT and PET/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: initial experience A Afshar-Oromieh, U Haberkorn, HP Schlemmer, M Fenchel, M Eder, ... European journal of nuclear medicine and molecular imaging 41, 887-897, 2014 | 377 | 2014 |
| Multiparametric magnetic resonance imaging (MRI) and MRI–transrectal ultrasound fusion biopsy for index tumor detection: correlation with radical prostatectomy specimen JP Radtke, C Schwab, MB Wolf, MT Freitag, CD Alt, C Kesch, ... European urology 70 (5), 846-853, 2016 | 322 | 2016 |
| Apalutamide and overall survival in prostate cancer MR Smith, F Saad, S Chowdhury, S Oudard, BA Hadaschik, JN Graff, ... European urology 79 (1), 150-158, 2021 | 278 | 2021 |
| Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer WP Fendler, M Weber, A Iravani, MS Hofman, J Calais, J Czernin, H Ilhan, ... Clinical Cancer Research 25 (24), 7448-7454, 2019 | 250 | 2019 |
| The value of PSA density in combination with PI-RADS™ for the accuracy of prostate cancer prediction FA Distler, JP Radtke, D Bonekamp, C Kesch, HP Schlemmer, ... The Journal of urology 198 (3), 575-582, 2017 | 250 | 2017 |
| Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion … JP Radtke, TH Kuru, S Boxler, CD Alt, IV Popeneciu, C Huettenbrink, ... The Journal of urology 193 (1), 87-94, 2015 | 231 | 2015 |
| A novel stereotactic prostate biopsy system integrating pre-interventional magnetic resonance imaging and live ultrasound fusion BA Hadaschik, TH Kuru, C Tulea, P Rieker, IV Popeneciu, ... The Journal of urology 186 (6), 2214-2220, 2011 | 228 | 2011 |
| Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer TH Kuru, MC Roethke, J Seidenader, T Simpfendörfer, S Boxler, ... The Journal of urology 190 (4), 1380-1386, 2013 | 224 | 2013 |
| Radiomic machine learning for characterization of prostate lesions with MRI: comparison to ADC values D Bonekamp, S Kohl, M Wiesenfarth, P Schelb, JP Radtke, M Götz, ... Radiology 289 (1), 128-137, 2018 | 214 | 2018 |
| Clinical relevance and suppressive capacity of human myeloid-derived suppressor cell subsets S Lang, K Bruderek, C Kaspar, B Höing, O Kanaan, N Dominas, ... Clinical Cancer Research 24 (19), 4834-4844, 2018 | 212 | 2018 |
